The 11β-hydroxysteroid dehydrogenase type II enzyme: Biochemical consequences of the congenital R337C mutation

Steroids

Volumn 61, Issue 4, 1996, Pages 197-200

  Ferrari, Paolo ^a   Obeyesekere, Varuni R ^a   Li, Kevin ^a   Andrews, Robert K ^a   Krozowski, Zygmunt S ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

11 hydroxysteroid dehydrogenase; glucocorticoid; mineralocorticoid; mutation

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; HYDROCORTISONE;

CELL FREE SYSTEM; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME STABILITY; MUTATION; PROTEIN SYNTHESIS INHIBITION; SODIUM RETENTION; STEROID METABOLISM;

GLYCYRRHIZA;

EID: 0029935189     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0039-128X(96)00013-X     Document Type: Conference Paper

References (23)

1. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM (1992). A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262-265.
2. Shimkets RA, Warnock DG, Bositis CM, Nelson WC, Hansson JH, Schambelan M, Gill JJ, Ulick S, Milora RV, Findling JW, Canessa CM, Rossier BC, and Lifton RP (1994). Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79:407-414.
3. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghyazar M, Harbison MD, Wei JQ, Shackleton C, Funder JW, New MI (1995). A mutation in the HSD11b2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80:2263-2266.
4. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC (1995). Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 10:394-399.
5. Obeyesekere VR, Ferrari P, Andrews RK, Wilson RC, New MI, Funder JW, Krozowski ZS (1995). The R337C mutation generates a high Km 11beta-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80:3381-3383.
6. Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shackleton CH, Hanauske-Abel HM, Wei JQ, Hertecant J, Moran A, Nieberger RE, Williamson Balfe J, Fattah A, Daneman D, Licholai T, New MI (1995). Several homozygous mutations in the gene for 11betahydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrin Metab 80:3145-3150.
7. Krozowski ZS, Funder JW (1983). Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 80:6056-6060.
8. Edwards CRW, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, deKloet ER, Monder C (1988). Localisation of 11 betahydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 2:986-989.
9. Funder JW, Pearce PT, Smith R, Smith AI (1988). Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585.
10. Krozowski Z, Maguire JA, Stein-Oakley AN, Dowling J, Smith RE, Andrews RK (1995). Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab 80:2203-2209.
11. Barker DJ, Bull AR, Osmond C, Simmonds SJ (1990). Fetal and placental size and risk of hypertension in adult life. Brit Med J 301:259-262.
12. Edwards C, Benediktsson R, Lindsay RS, Seckl JR (1993). Dysfunction of placental glucocorticoid barrier - link between fetal environment and adult hypertension. Lancet 341:355-357.
13. Stewart PM, Rogerson FM, Mason JI (1995). Type 2 11 betahydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J Clin Endocrinol Metab 80:885-890.
14. O'Banion MK, Sadowski HB, Winn V, Young DA (1991). A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 266:23261-23267.
15. Bradford M (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein dye binding. Anal Biochem 72:248-254.
16. Zhou XY, Galjart NJ, Willemsen R, Gillemans N, Galjaard H, d'Azzo A (1991). A mutation in a mild form of galactosialidosis impairs dimerization of the protective protein and renders it unstable. EMBO J 10:4041-4048.
17. Krozowski Z (1994). The short-chain alcohol dehydrogenase superfamily: variations on a common theme. J Steroid Biochem Mol Biol 51:125-130.
18. Jornvall H, Persson B, Krook M, Atrian S, Gonzalezduarte R, Jeffery J, Ghosh D (1995). Short-chain dehydrogenase reductases (SDR). Biochemistry 34:6003-6013.
19. Roland BL, Li K, Funder JW (1995). Hybridization histochemical localization of 11 beta-hydroxysteroid dehydrogenase type 2 in rat brain. Endocrinology 136:4697-4700.
20. Ullian ME, Walsh LG (1995). Corticosterone metabolism and effects on angiotensin II receptors in vascular smooth muscle. Circ Res 77:702-709.
21. Morris DJ, Semafuko WE, Latif SA, Vogel B, Grimes CA, Sheff MF (1992). Detection of glycyrrhetinic acid-like factors (GALFs) in human urine. Hypertension 20:356-360.
22. Soro A, Ingram MC, Tonolo G, Glorioso N. Fraser R (1995). Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension. Hypertension 25:67-70.
23. Walker BR, Stewart PM, Shackleton CH, Padfield PL, Edwards CR (1993). Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol (Oxf), 39: 221-227.